Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML |
Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD |
Reach Grants |
2017 |
Wisconsin |
Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor |
Ann & Robert H. Lurie Children’s Hospital of Chicago / Rintaro Hashizume, MD/PhD |
Reach Grants |
2018 |
Illinois |
Enhancing TKI Therapy in Ph-Like Leukemia |
The Regents of the University of California, Irvine / David Fruman, PhD |
Reach Grants |
2022 |
California |
Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL |
University of Rochester / Carol Fries Simpson, MD |
Reach Grants |
2023 |
New York |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia |
Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD |
Reach Grants |
2015 |
Massachusetts |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |